Diabetes mellitus secondary to treatment with immune checkpoint inhibitors.
We present a patient with type 1 diabetes mellitus secondary to immunotherapy, together with an overview of the associated literature. Patients who develop type 1 diabetes mellitus experience a rapid course, and diabetic ketoacidosis is commonly the presenting symptom. Insulin is currently the treatment of choice; oral antidiabetics or corticosteroids do not assist in management. Several predictive factors are under investigation, but physician awareness and prompt management are key to a positive outcome.
PMID: 30853817 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Corticosteroid Therapy | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Endocrinology | Immunotherapy | Insulin | Oral Cancer | Thyroid | Thyroid Cancer | Toxicology